Bial – Portela & Ca SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bial - Portela & Ca SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10823
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ポルトガル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bial – Portela & Ca SA (BIAL) is a pharmaceutical company that discovers, develops and provides drugs for neurosciences and cardiovascular therapeutic areas. The company offers products such as anti-inflammatories, anti-diabetics, cardiovascular, anti-asthmatics, antibiotics, antidepressants and anti-anemics, among others. Its products find its application in various therapeutic areas such as antibiotic therapy, cardiovascular diseases, central nervous system, immunotherapy, musculoskeletal system, and respiratory disease. BIAL offers services such as research, development, scientific research, integrity rigor and administration of the RDI management system, among others. The company has its presence in Angola, Cote d’Ivoire, Germany, Italy, Mozambique, Panama, Poland, Spain, Switzerland, and the UK. BIAL is headquartered in Porto, Portugal.

Bial – Portela & Ca SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bial – Portela & Ca SA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Bial – Portela Acquires Business Unit from Grupo Juste 10
Partnerships 11
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 11
Licensing Agreements 12
WhanIn Pharma Enters into Licensing Agreement with Bial – Portela 12
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial – Portela 13
Neurocrine Biosciences Enters into Licensing Agreement with Bial 14
BIAL Enters into Licensing Agreement with Helsinn 15
Bial Enters into Licensing Agreement with Moksha8 Pharma for Eslicarbazepine Acetate 16
Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 17
Acquisition 18
Roxall Medizin to Acquire Bial-Aristegui from Bial – Portela & Ca 18
Bial – Portela & Ca SA – Key Competitors 19
Bial – Portela & Ca SA – Key Employees 20
Bial – Portela & Ca SA – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Key Facts 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bial - Portela & Ca SA, Deals By Therapy Area, 2012 to YTD 2018 8
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bial - Portela Acquires Business Unit from Grupo Juste 10
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 11
WhanIn Pharma Enters into Licensing Agreement with Bial - Portela 12
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial - Portela 13
Neurocrine Biosciences Enters into Licensing Agreement with Bial 14
BIAL Enters into Licensing Agreement with Helsinn 15
Bial Enters into Licensing Agreement with Moksha8 Pharma for Eslicarbazepine Acetate 16
Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 17
Roxall Medizin to Acquire Bial-Aristegui from Bial - Portela & Ca 18
Bial - Portela & Ca SA, Key Competitors 19
Bial - Portela & Ca SA, Key Employees 20
Bial - Portela & Ca SA, Subsidiaries 21

List of Figures
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bial - Portela & Ca SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Bial – Portela & Ca SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Okklo Life Sciences BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Okklo Life Sciences BV (Okklo) is a biopharmaceutical company that develops novel therapeutic solutions. The company offers cyclodextrin-based medicines for the treatment of neglected and orphan diseases. It also develops therapeutics for infectious diseases and lysosomal storage diseases. O …
  • Academy Sports + Outdoors:企業の戦略・SWOT・財務情報
    Academy Sports + Outdoors - Strategy, SWOT and Corporate Finance Report Summary Academy Sports + Outdoors - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Hitachi Ltd (6501):電力:M&Aディール及び事業提携情報
    Summary Hitachi Ltd (Hitachi) is a multinational company with operations in sectors such as engineering and electronics, nuclear, transportation and industrial systems. It manufactures and sells information and telecommunication systems, power systems, social infrastructure and industrial systems, c …
  • Bc Hydro:企業の戦略・SWOT・財務分析
    Bc Hydro - Strategy, SWOT and Corporate Finance Report Summary Bc Hydro - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Magnit:企業の戦略・SWOT・財務情報
    Magnit - Strategy, SWOT and Corporate Finance Report Summary Magnit - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • ALung Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary ALung Technologies Inc (ALung Technologies) is a medical device company that develops devices for treating patients with acute respiratory failure. The company's Hemolung Respiratory Assist System(RAS) provides respiratory dialysis that removes carbon dioxide and delivers oxygen directly to …
  • Central Garden & Pet Co (CENT):企業の財務・戦略的SWOT分析
    Central Garden & Pet Co (CENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • ChemRar High-Tech Center:製薬・医療:M&Aディール及び事業提携情報
    Summary ChemRar High-Tech Center (CHTC) is a developer of drugs for life-threatening diseases. The company offers drugs for the treatment of cancer, central nervous system, infectious, metabolic and cardiovascular diseases. It also offers pre-clinical and clinical research of new molecules including …
  • Bank of Singapore Ltd.:企業の戦略・SWOT・財務情報
    Bank of Singapore Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Singapore Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Aptevo Therapeutics Inc (APVO):製薬・医療:M&Aディール及び事業提携情報
    Summary Aptevo Therapeutics Inc (Aptevo), a subsidiary of Emergent Biosolutions Inc, is a biotechnology company that develops and commercializes oncology and hematology therapeutics. The company’s only marketed product Ixinity that is indicated to replace the missing clotting factor IX in adults and …
  • Hedberg Landscape & Masonry Supplies:企業の戦略的SWOT分析
    Hedberg Landscape & Masonry Supplies - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Mphasis Limited:企業の戦略・SWOT・財務分析
    Mphasis Limited - Strategy, SWOT and Corporate Finance Report Summary Mphasis Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Volkswagen AG (VOW3):企業の財務・戦略的SWOT分析
    Volkswagen AG (VOW3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Amazon.com, Inc.:企業の戦略・SWOT・財務情報
    Amazon.com, Inc. - Strategy, SWOT and Corporate Finance Report Summary Amazon.com, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Coty Inc.:企業の戦略・SWOT・財務分析
    Coty Inc. - Strategy, SWOT and Corporate Finance Report Summary Coty Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Qatar Airways Group Q.C.S.C.
    Qatar Airways Group Q.C.S.C. - Strategy, SWOT and Corporate Finance Report Summary Qatar Airways Group Q.C.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Enercon Services Inc:企業の戦略的SWOT分析
    Enercon Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Hostess Brands, Inc. (TWNK):企業の財務・戦略的SWOT分析
    Hostess Brands, Inc. (TWNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Innovacell Biotechnologie AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Innovacell Biotechnologie AG (Innovacell) is a biotechnology company that focuses on the development of therapeutic products. The company offers personalized cell therapy products for the treatment of incontinence. It provides medical products such as ICES13 and ICEF15. Innovacell’s products …
  • Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析
    Summary Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platf …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆